Yunnan Baiyao Group Co.,Ltd

000538

CNE0000008X7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
56.9 ^CNY	-0.14%		-0.61%	+15.77%

Apr. 30	Yunnan Baiyao Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2023, Payable on 10 May 2024	CI
Apr. 26	Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Yunnan Baiyao Group Co.,Ltd. Approves Cash Dividend for the Year 2023

April 23, 2024

Yunnan Baiyao Group Co.,Ltd. at its annual general meeting of 2023 on 23 April 2024, the company approved the cash dividend/10 shares (tax included) of CNY 20.77000000 for the year 2023.

Latest news about Yunnan Baiyao Group Co.,Ltd

Yunnan Baiyao Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2023, Payable on 10 May 2024	Apr. 29	CI
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Yunnan Baiyao Group Co.,Ltd. Approves Cash Dividend for the Year 2023	Apr. 23	CI
Yunnan Baiyao Group Co.,Ltd Proposes Final Cash Dividend for 2023	Apr. 01	CI
Yunnan Baiyao Group's Profit Rises 30% as Operating Income Increases	Apr. 01	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Shanghai Pharma, Yunnan Baiyao Renew Sales, Procurement Deal	Dec. 22	MT
Yunnan Baiyao’s Profit Jumps 61% in Q3 as Revenue Rises 5%	23-10-31	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
YNBY International Plans Year-End Date Change	23-10-16	MT
Yunnan Baiyao’s Profit Jumps 88.5% in H1 as Revenue Rises 13%	23-08-30	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Yunnan Baiyao Group Co.,Ltd. Approves Cash Dividend for the Year 2022, Payable on 19 May 2023	23-05-10	CI
Chinese Shares Rebound; Yunnan Baiyao Jumps 7.5% on Robust Q1 Earnings	23-04-27	MT
Yunnan Baiyao’s Q1 Profit Jumps 66% as Revenue Rises 11.5%; Shares Climb 7%	23-04-27	MT
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Yunnan Baiyao Group Co.,Ltd's Equity Buyback announced on May 9, 2022, has expired.	23-04-06	CI
Yunnan Baiyao Group Co.,Ltd Proposes Final Cash Dividend for 2022	23-03-31	CI
Yunnan Baiyao Chairman Steps Down; Shares Fall 4%	23-03-07	MT
Yunnan Baiyao Group Co.,Ltd agreed to acquire Product Registration and Promotion, Global Supply and Professional Supporting Services of Ban Loong from Ban Loong Holdings Limited (SEHK:30).	22-12-22	CI
Yunnan Baiyao Group Co.,Ltd Announces Directorate Appointments	22-11-08	CI
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Yunnan Baiyao Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Yunnan Baiyao to Use Huawei’s AI Tech in Developing Drugs	22-07-25	MT
Yunnan Baiyao Group Co.,Ltd announces a Decrease in Equity Buyback.	22-06-01	CI

Chart Yunnan Baiyao Group Co.,Ltd

Duration

Period

More charts

Yunnan Baiyao Group Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily traditional medicine products, phytobiological products, body care products, antibiotics and anti-inflammatory. China accounts for 98.9% of net sales.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Yunnan Baiyao Group Co.,Ltd

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

56.9 CNY

Average target price

64.08 CNY

Spread / Average Target

+12.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
YUNNAN BAIYAO GROUP CO.,LTD	+15.77%	14.09B
ELI LILLY AND COMPANY	+32.95%	700B
NOVO NORDISK A/S	+26.51%	569B
JOHNSON & JOHNSON	-4.97%	358B
MERCK & CO., INC.	+18.83%	330B
ABBVIE INC.	+3.54%	287B
ASTRAZENECA PLC	+15.70%	236B
NOVARTIS AG	+6.68%	202B
ROCHE HOLDING AG	-9.08%	197B
AMGEN INC.	+6.70%	161B

Other Pharmaceuticals